Atos International: Pierre Fabre chooses Atos OneCloud to support its ambitions in digital transformation, cybersecurity and decarbonization finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
(0)
BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunology located in Saint-Julien-en-Genevois (France), with the aim of treating patients suffering from TED. Other indications in rare diseases could also be developed by ValenzaBio. In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.
Puma Biotechnology, Inc : Puma Biotechnology and Pierre Fabre Amend NERLYNX License Agreement to Include Greater China finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Program/Project Management Job in CAR about Gender and Protection and Human Rights, requiring 10+ years of experience, from Dr. Denis Mukwege Foundation; closing on 28 Feb 2021
Pierre Fabre Selects AGC Biologics as CDMO to manufacture the orphan drug ER-004 | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.